Published in J Clin Oncol on January 01, 1997
Capecitabine in Metastatic Breast and GI Cancers (X7-7) | NCT02595320
Health Course of Patients Undergoing Per os Anti-cancer Therapy. (MinOS) | NCT03454971
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes (2004) 3.95
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer (2003) 1.95
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer (2000) 1.93
2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract (2013) 1.58
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence (2010) 1.55
Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer (2002) 1.44
Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis. World J Surg Oncol (2017) 1.40
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer (2006) 1.39
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer (2002) 1.24
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer (2006) 1.22
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer (2006) 1.21
Capecitabine: preclinical pharmacology studies. Invest New Drugs (2000) 1.10
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol (2008) 1.06
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci (2011) 1.05
Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis (2007) 1.00
Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol (2015) 0.99
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. Br J Cancer (2006) 0.99
A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol (2014) 0.97
Acceptance of oral chemotherapy in breast cancer patients - a survey study. BMC Cancer (2011) 0.96
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer (2012) 0.95
Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist (2014) 0.95
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer (2009) 0.94
Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol (2014) 0.92
Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J Control Release (2011) 0.91
Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. J Oncol Pract (2012) 0.91
Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist (2014) 0.91
Oral delivery of taxanes. Invest New Drugs (2001) 0.90
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. Br J Cancer (2008) 0.90
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer (2004) 0.90
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol (2005) 0.89
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol (2009) 0.89
Active home-based cancer treatment. J Multidiscip Healthc (2012) 0.89
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence (2014) 0.88
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J (2006) 0.88
Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. Int J Clin Pharm (2013) 0.87
The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer (2011) 0.87
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol (2011) 0.87
Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. J Clin Oncol (2015) 0.87
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer (2015) 0.87
Interventions to promote adherence with oral agents. Semin Oncol Nurs (2011) 0.86
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol (2006) 0.86
pH-Responsive Hydrogels with Dispersed Hydrophobic Nanoparticles for the Delivery of Hydrophobic Therapeutic Agents. Polym Int (2012) 0.86
Development of oral cladribine for the treatment of multiple sclerosis. J Neurol (2010) 0.86
Prescribing oral chemotherapy. BMJ (2007) 0.86
Impact of clinical oral chemotherapy program on wastage and hospitalizations. J Oncol Pract (2011) 0.86
Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res (2011) 0.85
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer (2009) 0.85
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci (2006) 0.85
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer (2004) 0.85
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer (2012) 0.84
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer (2004) 0.84
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer (2010) 0.83
Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat (2004) 0.83
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest New Drugs (2000) 0.83
Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions. Radiol Oncol (2013) 0.82
Amphiphilic Interpenetrating Networks for the Delivery of Hydrophobic, Low Molecular Weight Therapeutic Agents. Ind Eng Chem Res (2011) 0.82
Pre-operative radiochemotherapy of locally advanced rectal cancer. World J Gastroenterol (2003) 0.82
Capecitabine in the management of colorectal cancer. Cancer Manag Res (2011) 0.81
pH-responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics. J Biomed Mater Res A (2012) 0.81
Transbuccal delivery of 5-fluorouracil: permeation enhancement and pharmacokinetic study. AAPS PharmSciTech (2009) 0.80
Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Medicine (Baltimore) (2015) 0.80
Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv (2015) 0.80
Efficacy, compliance and reasons for refusal of postoperative chemotherapy for elderly patients with colorectal cancer: a retrospective chart review and telephone patient questionnaire. PLoS One (2013) 0.80
Combination therapy of S-1 and CDDP for patients with colorectal cancer. J Cancer Res Clin Oncol (2007) 0.80
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist (2012) 0.79
Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Prefer Adherence (2014) 0.79
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clin Pharmacokinet (2016) 0.79
"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Invest New Drugs (2014) 0.79
Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients. Int J Clin Oncol (2012) 0.79
Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis. Curr Oncol (2011) 0.78
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res (2016) 0.78
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer (2003) 0.78
Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer Res Treat (2004) 0.78
Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. AAPS J (2016) 0.78
Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial. JMIR Res Protoc (2014) 0.78
A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag (2007) 0.78
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma (2013) 0.78
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. Anticancer Drugs (2012) 0.78
Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients. Patient Prefer Adherence (2013) 0.78
The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries. BMC Psychiatry (2016) 0.77
pH-responsive hydrogels containing PMMA nanoparticles: an analysis of controlled release of a chemotherapeutic conjugate and transport properties. J Biomater Sci Polym Ed (2012) 0.77
The use of capecitabine in daily practice: a study on adherence and patients' experiences. Patient Prefer Adherence (2012) 0.77
Characterizing drug-metabolizing enzymes and transporters that are bona fide CAR-target genes in mouse intestine. Acta Pharm Sin B (2016) 0.77
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. Br J Cancer (2001) 0.77
Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development. JMIR Res Protoc (2017) 0.76
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. Br J Cancer (2004) 0.76
Intestinal absorption characteristics of imperialine: in vitro and in situ assessments. Acta Pharmacol Sin (2015) 0.76
Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. J Skin Cancer (2015) 0.76
Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment in Turkey. Support Care Cancer (2006) 0.76
Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ (2004) 0.75
Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Sci Rep (2017) 0.75
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res (2009) 0.75
β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells. Oncotarget (2016) 0.75
Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag (2008) 0.75
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Br J Cancer (2005) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Benefits and risks of circumcision. Can Med Assoc J (1981) 3.49
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J (2007) 2.83
Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol (1996) 2.78
A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas (1996) 2.74
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry (1987) 2.65
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Patients either contacting a general practice cooperative or accident and emergency department out of hours: a comparison. Emerg Med J (2006) 1.79
Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys (1999) 1.69
Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract (2000) 1.54
Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) (2001) 1.53
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology (1996) 1.42
Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol (1995) 1.41
Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol (1995) 1.40
Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci (1997) 1.39
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol (2000) 1.19
Patient-health care provider communication during chemotherapy treatment: the perspectives of women with breast cancer. Patient Educ Couns (2001) 1.17
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer (2012) 1.15
Early postsurgery experience of prostate cancer patients and spouses. Cancer Pract (2002) 1.13
The role of belief in healing. Can Med Assoc J (1983) 1.12
Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer (1996) 1.11
Ingestion of angel's trumpet: an increasingly common source of toxicity. South Med J (1996) 1.06
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol (2000) 1.06
Young family physicians support hospital-based activities. Can Fam Physician (1995) 1.02
Laboratory investigations in general practice. Can Fam Physician (1993) 1.02
Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat (2001) 0.99
Development of a knowledge scale about breast cancer and heredity (BCHK). Breast Cancer Res Treat (1999) 0.99
The APCI1307K allele and breast cancer risk. Nat Genet (1998) 0.99
Prospective assessment of symptom palliation for patients attending a rapid response radiotherapy program. feasibility of telephone follow-up. J Pain Symptom Manage (2001) 0.98
Successful management of chronic intestinal pseudo-obstruction with home parenteral nutrition. JPEN J Parenter Enteral Nutr (1985) 0.97
A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol (1998) 0.95
Referring physicians' satisfaction with the rapid response radiotherapy programme. Survey results at the Toronto-Sunnybrook Regional Cancer Centre. Support Care Cancer (2000) 0.95
Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.93
Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet (2000) 0.93
A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas (1996) 0.92
Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. Can Fam Physician (1999) 0.92
Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol (2013) 0.91
Comparing treatment outcomes of radiotherapy and surgery in locally advanced carcinoma of the larynx: a comparison limited to patients eligible for surgery. Int J Radiat Oncol Biol Phys (2000) 0.91
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol (2003) 0.90
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med (1993) 0.90
Can breast MRI computer-aided detection (CAD) improve radiologist accuracy for lesions detected at MRI screening and recommended for biopsy in a high-risk population? Clin Radiol (2009) 0.89
Patients' knowledge of and attitudes toward the management of cancer pain. Oncol Nurs Forum (1998) 0.89
Prediction of obliteration of arteriovenous malformations after radiosurgery: the obliteration prediction index. Can J Neurol Sci (1997) 0.89
The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog Clin Biol Res (1989) 0.89
Percutaneous diagnosis and drainage of pylephlebitis: a case report. Surgery (1987) 0.89
Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol (1995) 0.87
Utilization of professional supportive care services by women with breast cancer. Breast Cancer Res Treat (2000) 0.87
Breast cancer detection practices of south Asian women: knowledge, attitudes, and beliefs. Oncol Nurs Forum (1999) 0.87
Hereditary breast cancer. Psychosocial issues and family physicians' role. Can Fam Physician (1999) 0.87
Free forearm flap in oral reconstruction. Functional outcome. Arch Otolaryngol Head Neck Surg (1995) 0.87
Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res (1995) 0.87
Management of women at increased risk for breast cancer: preliminary results from a new program. CMAJ (1997) 0.86
Perspectives on living with ovarian cancer: older women's views. Oncol Nurs Forum (2001) 0.86
Dementia staging in chronic care populations. Alzheimer Dis Assoc Disord (1994) 0.86
Needs of family caregivers of patients receiving home hospice care for cancer. Oncol Nurs Forum (1996) 0.86
pynk : Breast Cancer Program for Young Women. Curr Oncol (2013) 0.85
A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol (1997) 0.85
Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy. Int J Radiat Oncol Biol Phys (2001) 0.84
Measuring patient outcomes in palliative care: a reliability and validity study of the Support Team Assessment Schedule. Palliat Med (2000) 0.83
The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet (1999) 0.83
Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer (2000) 0.83
Ratio of female to male offspring of women tested for BRCA1 and BRCA2 mutations. J Med Genet (2004) 0.83
Men's perspectives on the impact of prostate cancer: implications for oncology nurses. Oncol Nurs Forum (2000) 0.83
An ordinal functional assessment tool for Alzheimer's-type dementia. Hosp Community Psychiatry (1985) 0.83
The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage. Int J Radiat Oncol Biol Phys (1998) 0.82
Continuous epidural narcotic analgesia for intractable pain due to malignancy. J Surg Oncol (1985) 0.82
Prospective patient-based assessment of effectiveness of palliative radiotherapy for bone metastases. Radiother Oncol (2001) 0.82
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol (1992) 0.82
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer (1998) 0.81
Remediable behavioral symptomatology in Alzheimer's disease. Hosp Community Psychiatry (1986) 0.81
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res (1998) 0.81
Perspectives on living with ovarian cancer: young women's views. Can Oncol Nurs J (2000) 0.81
Predicting postlaryngectomy voice outcome in an era of primary tracheoesophageal fistulization: a retrospective evaluation. J Otolaryngol (1997) 0.80
Coping strategies of family caregivers of home hospice patients with cancer. Oncol Nurs Forum (1996) 0.80
Development and pilot testing of an online intervention to support young couples' coping and adjustment to breast cancer. Eur J Cancer Care (Engl) (2014) 0.80
Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada. Clin Breast Cancer (2000) 0.79
Gynecologists' perspectives regarding ovarian cancer. Cancer Prev Control (1999) 0.79
Case report: hypothalamic tuberculoma associated with secondary panhypopituitarism. Am J Med Sci (1993) 0.79
Use of the CAGE questionnaire for screening problem drinking in an out-patient palliative radiotherapy clinic. J Pain Symptom Manage (2001) 0.79
Intradural granulocytic sarcoma presenting as a lumbar radiculopathy. Case report. J Neurosurg (1990) 0.78
Attitudes of Canadian radiation oncologists towards post-lumpectomy radiotherapy for elderly women with stage I hormone-responsive breast cancer. Clin Oncol (R Coll Radiol) (2009) 0.78
VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. Eur J Cancer (1994) 0.78
Survivors' perspectives on the impact of prostate cancer: implications for oncology nurses. Can Oncol Nurs J (1999) 0.78
Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol (1994) 0.78
A mixed-methods cohort study to determine perceived patient benefit in providing custom breast prostheses. Curr Oncol (2012) 0.77
Fighting the battle against breast cancer. So close and yet so far. Can Fam Physician (1999) 0.77
Cancer treatment-induced menopause: meaning for breast and gynecological cancer survivors. Can Oncol Nurs J (2000) 0.77
Delineation of brain metastases on CT images for planning radiosurgery: concerns regarding accuracy. Br J Radiol (2004) 0.77
Bronchogenic carcinoma in patients seropositive for human immunodeficiency virus. Chest (1994) 0.77